IDEXX Laboratories Reports Strong Q1 2026 Results with Double-Digit Revenue and EPS Growth
summarizeSummary
IDEXX Laboratories reported strong first-quarter 2026 financial results, with double-digit increases in revenue, net income, and diluted EPS, reinforcing a positive outlook for the year.
check_boxKey Events
-
Strong Q1 Financial Performance
Total revenue increased by 14.3% to $1,140.8 million, net income rose by 14.7% to $278.4 million, and diluted EPS grew by 17.2% to $3.47 compared to Q1 2025.
-
Broad-Based Segment Growth
All reportable segments contributed to revenue growth, with the Companion Animal Group (CAG) leading at a 14.6% increase (11.6% organic), followed by Water at 10.9% (7.1% organic) and LPD at 13.6% (7.2% organic).
-
Active Capital Management
The company repurchased $351.0 million of common stock during the quarter, while net borrowings under its credit facility increased to $132.0 million. Working capital decreased to $154.2 million, primarily due to higher borrowings.
-
Solid Liquidity and Debt Position
IDEXX maintains $718.2 million in remaining borrowing availability under its $1.25 billion credit facility and is in compliance with all debt covenants. Upcoming senior note maturities of $75.0 million in September 2026 and $75.0 million in February 2027 are expected to be funded with available cash, credit facility, or new notes.
auto_awesomeAnalysis
IDEXX Laboratories delivered robust financial performance in the first quarter of 2026, with significant double-digit growth across key metrics. This 10-Q filing provides the detailed financial statements supporting the strong results, which were previously indicated by news and an 8-K filing on the same day. The company's core Companion Animal Group (CAG) segment was a primary driver of revenue growth, complemented by solid performance in Water and Livestock, Poultry and Dairy (LPD) segments. While the company increased borrowings under its credit facility and saw a decrease in working capital, it maintains substantial liquidity and remains in compliance with all debt covenants. The outlook for the remainder of 2026 is positive, with anticipated favorable impacts from foreign currency exchange rates on revenue, operating profit, and diluted EPS.
At the time of this filing, IDXX was trading at $562.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.7B. The 52-week trading range was $465.00 to $769.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.